Mechanism of Inhibition of Novel Tryptophan Hydroxylase Inhibitors Revealed by Co-crystal Structures and Kinetic Analysis
Cianchetta, G., Stouch, T., Yu, W., Shi, Z.-C., Tari, L.W., Swanson, R.V., Hunter, M.J., Hoffman, I.D., Liu, Q.(2010) Bioorg Med Chem Lett 4: 19-26
- PubMed: 19631532 
- DOI: https://doi.org/10.1016/j.bmcl.2009.07.005
- Primary Citation of Related Structures:  
3HF6 - PubMed Abstract: 
Tryptophan hydroxylase (TPH) is a key enzyme in the synthesis of serotonin. As a neurotransmitter, serotonin plays important physiological roles both peripherally and centrally. Here we describe the discovery of substituted triazines as a novel class of tryptophan hydroxylase inhibitors. This class of TPH inhibitors can selectively reduce serotonin levels in murine intestine after oral administration without affecting levels in the brain. These TPH inhibitors may provide novel treatments for gastrointestinal disorders associated with dysregulation of the serotonergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.
Organizational Affiliation: 
Lexicon Pharmaceuticals, 350 Carter Road, Princeton, NJ 08540, USA. hjin@lexpharma.com